Study of the Thyroid Gland's Cyclin D1 (Immune Histochemical Approach)
DOI:
https://doi.org/10.56981/Abstract
One of the most common tumors is thyroid cancer many factors contributed to this cancer one of them is cyclin dependent kinases 1 (CDKs1) which play a role in regulation of cell cycle. The study was aimed to evaluate the expression of CDK1 in thyroid carcinoma by immunohistochemical technique. There were 100 individuals enrolled in this study divided into two groups : patients with thyroid cancer 50 (20 benign thyroid cancer , 30 malignant thyroid cancer) and 50 controls as second group from October 2021 till April 2022 at Imam Hussein medical city Karbala Iraq. The thyroid tissue sample of all individual were undergone for immune histochemistry test for CDK1. The result showed significant difference (P value ˂ 0.00001) in expression of CDK1 between benign and malignant thyroid cancer their expression in benign cases 8(40%), for malignant cases 14(46.1%) {(10 (33.33%) classical type and 4(13.33%) follicular type} only 9 (30%) while only 1% of benign cases were strong staining. All apparently healthy thyroid tissue was negative for expression of CDK1. The study was concluded that Cyclin D1 overexpressed in Papillary thyroid carcinoma in comparison with follicular adenoma.
References
1. Bièche, I., et al., Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid, 2001. 11(2): p. 147-152.
2. Casimiro, M.C., et al., Cyclins and cell cycle control in cancer and disease. Genes & cancer, 2012. 3(11-12): p. 649-657.
3. Li, H., et al., LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway. Cell death & disease, 2018. 9(2): p. 1-15.
4. Erickson, L.A., et al., Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Modern Pathology, 2000. 13(2): p. 186-192.
5. Zou, T. and Z. Lin, The involvement of ubiquitination machinery in cell cycle regulation and cancer progression. International Journal of Molecular Sciences, 2021. 22(11): p. 5754.
6. Perisanidis C, Perisanidis B, Wrba F. Evaluation of Immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med. 2012;41:40–6 .
7. Wang, S., et al., The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Modern Pathology, 2000. 13(8): p. 882-887.
8. Liu Z, Zhou G, Nakamura M, Koike E, Li Y, Ozaki T, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011;102(1):288–94.
9. He, Y., et al., Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer research, 2007. 67(17): p. 8188-8197.
10. Ben-Salem, S., V.B. Venkadakrishnan, and H.V. Heemers, Novel insights in cell cycle dysregulation during prostate cancer progression. Endocrine-related cancer, 2021. 28(6): p. R141-R155.
11. Wei, Z.-l., et al., Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC gastroenterology, 2022. 22(1): p. 1-17.
12. Jiang, W., et al., Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer research, 1992. 52(10): p. 2980-2983.
13. Khoo, M.L., et al., Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 2002. 87(4): p. 1814-1818.
14. Lazzereschi, D., et al., Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. International journal of cancer, 1998. 76(6): p. 806-811.
15. Meredith, S.D., et al., Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Archives of Otolaryngology–Head & Neck Surgery, 1995. 121(7): p. 790-794.
16. Kim, J.Y., et al., Expression of CD44 and cyclin D1 in fine needle aspiration cytology of papillary thyroid carcinoma. Acta cytologica, 2002. 46(4): p. 679-683.
17. Nakashima, M., et al., Cyclin D1 overexpression in thyroid tumours from a radio‐contaminated area and its correlation with Pin1 and aberrant β‐catenin expression. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2004. 202(4): p. 446-455.
18. Pickett, C.A., et al., Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid, 2005. 15(5): p. 461-473.
19. Seybt, T.P., et al., Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: diagnostic and biologic implications. Applied Immunohistochemistry & Molecular Morphology, 2012. 20(2): p. 124-130.
20. Sporny, S., D. Slowinska-Klencka, and M. Ratynska, Cyclin Dl expression in primary thyroid carcinomas. Neuroendocrinology Letters, 2005. 26(6): p. 815-818.
21. Timler, D., et al., Expression of proteins: D1 cyclin and Ki-67 in papillary thyroid carcinomas. Folia Histochemica et Cytobiologica, 2001. 39: p. 201-202.
22. Tong, R., et al., OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia. Oncology letters, 2017. 13(5): p. 2929-2936.
23. LiVolsi VA. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer. 2003;98:1997. author reply.
24. Zainab A.AL-Ali, As' ad A. Al-Janabi, Alaa. S. Jumaa,Pathological Study Of Renal Cell Carcinoma By Expression Of Vascular Endothelial Growth Factor (VEGF) And P53 (Immunohistochemical approach) Karbala Journal of Medicine,2011, Volume 4 no 2, Issue 10, Pages 1128-1132.
25. Muro-Cacho, C.A., et al., Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngology—Head and Neck Surgery, 1999. 120(2): p. 200-207.
26. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14(12): 3403–11.
27. Liu, Haiyan, and Fan Lin. "Application of Immunohistochemistry in Thyroid Pathology." Archives of Pathology & Laboratory Medicine, vol. 139, no. 1, Jan. 2015, p. 67. Gale Academic OneFile, link.gale.com/apps/doc/A511293668/AONE?u=anon~945de3dd&sid=googleScholar&xid=20e9d8cd. Accessed 11 Oct. 2022
28. Saiz AD, Olvera M, Rezk S, Florentine BA, Mc Courty A, Brynes RK.Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol. 2002;19:157–62
29. Franc, B., et al., Histological validation of diagnoses of thyroid cancer among adults in the registries of Belarus and the Ukraine. British journal of cancer, 2003. 89(11): p. 2098-2103.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 https://creativecommons.org/licenses/by/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
